Evidence map›Paper›PMID 32844323›Full record

ArticleAnnals of hematology2020

Evaluation of a screening program for iron overload and HFE mutations in 50,493 blood donors.

Carl Eckerström, Sofia Frändberg, Lena Lyxe, Cecilia Pardi, Jan Konar

Abstract read
In one paragraph

Article in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Carl EckerströmDepartment of Immunology and Transfusion medicine Region, Sahlgrenska University Hospital, Västra Götaland, Sweden. carl.eckerstrom@neuro.gu.se.ORCID http://orcid.org/0000-0002-3810-0520
Sofia FrändbergDepartment of Immunology and Transfusion medicine Region, Sahlgrenska University Hospital, Västra Götaland, Sweden.
Lena LyxeDepartment of Immunology and Transfusion medicine Region, Sahlgrenska University Hospital, Västra Götaland, Sweden.
Cecilia PardiDepartment of Immunology and Transfusion medicine Region, Sahlgrenska University Hospital, Västra Götaland, Sweden.
Jan KonarDepartment of Immunology and Transfusion medicine Region, Sahlgrenska University Hospital, Västra Götaland, Sweden.

Funding

Sahlgrenska Universitetssjukhuset ALFGBG-784831
6 · The paper itself

Abstract

Early detection of individuals with hereditary hemochromatosis (HH) is important to manage iron levels and prevent future organ damage. Although the HFE mutations that cause most cases of HH have been identified, their geographic distribution is highly variable, and their contribution to iron overload is not fully understood. All new registered blood donors at the Sahlgrenska University hospital between 1998 and 2015 were included in the study. Donors with signs of iron overload at baseline and subsequent follow-up testing were recommended genotyping of the HFE gene. Of the 50,493 donors that were included in the study, 950 (1.9%) had signs of iron overload on both test occasions. Of the 840 donors with iron overload that performed HFE genotyping, 117 were homozygous for C282Y, and 97 were compound heterozygotes. The prevalence of C282Y homozygosity was 0.23%. Iron overload screening effectively detects individuals at risk of carrying the C282Y mutation of the HFE gene and enables early treatment to prevent HH complications.

Indexed as

Blood DonorsMutation, MissenseAdultDonor SelectionEarly DiagnosisFemaleFerritinsGene FrequencyGenotypeHemochromatosisHemochromatosis ProteinHumansMaleMiddle AgedProgram EvaluationSwedenFerritinsHemochromatosis ProteinHFE protein, humanBlood donorsHereditary hemochromatosisHFEScreening program

Identifiers

PMID32844323
PMCPMC7481153

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.